What Phesi does

Phesi is a privately held, founder-controlled clinical data science company founded in 2007 by Dr. Gen Li (formerly Head of Productivity at Pfizer Worldwide Clinical Development) and headquartered in East Lyme, Connecticut, with operational offices in Boston, New York, Amsterdam, and London. The company sells AI-powered clinical development analytics to pharmaceutical companies, biotechnology firms, and contract research organizations, with a disclosed customer base spanning all top-10 global pharma (Pfizer, Merck, Sanofi, Novartis, J&J, BMS, Bayer, Takeda, Lilly, and others) plus a broad set of biotechs including Biogen, Incyte, Alexion, Silence Therapeutics, and MannKind.

The company's core product is the patented Trial Accelerator platform, an AI-driven operating system that processes the world's largest contextualized clinical trials database (485,000+ curated trials, 325+ million patient records, 4.2 million physicians, 4,000+ disease indications, 195 countries, 100+ dynamically updated sources) to deliver predictive modeling across four views: Patient Profile, Trial Performance, Country, and Investigator Site. Built on this data asset are specialized modules for protocol design optimization (modal value-based design), Digital Twin and External Control Arm generation (synthetic control arms from digital patient profiles), investigator and country site selection (via the proprietary Patient Access Score), a DE&I Data Service for diversity planning, and a Health Check/Trial Rescue Service for at-risk trials. Documented outcomes include 22-month to 16.5-month enrollment reduction in an iron-overload case study, $5M+ savings in a ulcerative colitis rescue, and support for FDA-approved drugs including Keytruda, Besponsa, Plegridy, Adlyxin, PREVYMIS, and Xofluza.

Phesi operates a subscription-based enterprise licensing model with quote-based annual contracts and no publicly disclosed pricing tiers. Go-to-market is direct enterprise field sales through sales specialists in Boston, NY, Amsterdam, and London with remote work options, supported by thought leadership at industry conferences (ASCO, ESMO, SCOPE, DPHARM, J.P. Morgan Healthcare Conference) and research publications including annual most-studied disease reports and peer-reviewed articles in Applied Clinical Trials and Nature. The company has earned consecutive analyst recognition (Frost & Sullivan Best Practices Award 2024, Clinical Trials Arena Innovation Award 2025, Frost Radar Global Growth Leader 2026), holds EU-U.S., UK Extension, and Swiss-U.S. Data Privacy Framework certifications, and is profitable/bootstrapped with no external funding rounds or parent company disclosed.

Name

Phesi

Legal name

Pharmaceutical Pipeline Enhancement Strategies, LLC

Website

https://phesi.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Phesi is a privately held clinical data science company that provides an AI-powered Trial Accelerator platform using the world's largest contextualized clinical trials database (325M+ patients, 485K+ trials) to optimize protocol design, site selection, and external control arms for pharmaceutical, biotechnology, and CRO clients, including all top-10 global pharma.

Ownership category

akta.pro rank

Product category

Clinical Trial Analytics Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

akta.pro secondary industries

Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Clinical trial analytics
• AI drug development
• Digital patient profiles
• Protocol design optimization
• Site selection software

Headquarters

HQ city

East Lyme

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Trial Accelerator Platform Licensing: Subscription-based licensing of the Trial Accelerator platform to pharmaceutical, biotech, and CRO clients. Platform access enables protocol optimization, site selection, and trial simulation services. Clients include top 5 pharma companies and biotech startups.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Phesi provides an AI-powered Trial Accelerator platform that delivers patient-centric clinical development analytics for pharmaceutical, biotechnology, and CRO clients. The platform leverages the world's largest contextualized clinical trials database (465,000+ curated trials, 325+ million patient records across 195 countries) to enable protocol design optimization, digital patient profiling, digital twins, external control arms, and investigator site selection. Core service modules support clinical trial design, execution, and rescue operations for drug development sponsors.

Product overview

Phesi offers a unified platform-plus-services architecture centered on the Trial Accelerator Platform, an AI-driven operating system that delivers integrated patient-centric analytics across four sequential views: Patient, Trial Performance, Country, and Investigator Site. The platform is supported by specialized service modules including Protocol Design and Optimization, Digital Twin and Digital Trial Arm, Countries and Investigator Site Selection, Strategic Development Planning, and DE&I Data Service. Complementary tools include the Trial Calculator for efficiency assessment and the Health Check and Trial Rescue Service for at-risk trial intervention. Key data products include Digital Patient Profiles (DPP) providing statistical views of patient populations, and the Patient Access Score for site performance measurement. The platform leverages data from hundreds of millions of patients across 195 countries and 4,000+ indications to enable predictive modeling, protocol optimization, and digital twin generation.

Differentiator

Problem solved

Functional benefit

Products and services

• Trial Accelerator Platform

Quantifiable outcome

• 26% of Phase II trials terminated (four-year low, still above pre-pandemic levels of ~20%)
• +8 more outcomes

Named customers22 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Veeva Systems: Veeva supplies a broad life-sciences cloud suite with clinical-data management and trial-operations products. It is an established incumbent that can bundle overlapping trial analytics and workflow capabilities.
• IQVIA: IQVIA is a global CRO and data-science company offering trial design, patient recruitment, site networks, and real-world data analytics. It is a broader incumbent with substantial overlap in Phesi's target customers and use cases.
• Oracle: Oracle's health-sciences portfolio includes EDC, clinical-trial management, data capture, and analytics. It is a broad incumbent competing for similar enterprise clinical-development budgets, although its platform is wider than Phesi's.
• Parexel: Parexel is a global CRO offering trial feasibility, patient recruitment, site selection, and digital-trial services. It is a broad incumbent comparable through the same pharmaceutical customers and trial-optimization use cases.

Direct peers

• Medidata: Medidata provides cloud software and analytics for clinical-trial data, study planning, feasibility, and patient and site operations. It is a close platform analogue to Phesi's Trial Accelerator and clinical-development analytics.
• TriNetX: TriNetX operates a global real-world data network used for protocol design, patient finding, site feasibility, and trial recruitment. It directly overlaps with Phesi's patient-centric analytics, real-world data, and investigator-site selection workflows.
• Certara: Certara provides biosimulation, regulatory science, and model-informed drug development, including synthetic-control and trial-design tools. It directly compares with Phesi's digital twins, digital trial arms, and simulation-led development planning.
• Cytel: Cytel provides biostatistics, statistical programming, data science, and trial-design services. Its trial-design and predictive-analytics capabilities closely compare with Phesi's protocol optimization and forecasting offerings.
• Saama: Saama provides an AI-enabled clinical-data analytics platform for clinical development, including data management and trial operations. It is a direct platform peer addressing similar pharmaceutical and biotechnology analytics workflows.

Emerging players

• Unlearn.ai: Unlearn.ai develops AI-generated digital twins of patients and historical control arms for clinical trials. It is a narrower technology peer whose digital-twin focus materially overlaps Phesi's corresponding product module.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/phesi_ct
• LinkedInlinkedin.com/company/phesi

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phesi